AMERSA

AMERSA

Call Us: (401) 615-4047 | Contact Us AMERSA on Twitter AMERSA on LinkedIn AMERSA on BlueSky

Make a Donation Pay a Past-Due Balance Join Our Mailing List
  • About
    • What is AMERSA
    • Board of Directors
    • Donate to AMERSA
    • Contact Us
  • Membership
    • Get to Know AMERSA
    • Join / Renew
    • Who We Are
    • Member Center
    • Special Interest Groups
    • Career Opportunities
    • Professional & Academic Advancement Opps
  • Conference
    • Annual Conference
    • Conference Sponsorship
    • Conference Exhibitor Information
    • Policy and Procedures for AMERSA Events
    • 2024 Conference Materials
    • Past Conference Resources
  • Journal
    • Journal Home
    • About Us
    • Member Access to Journal
    • Author Instructions and Submission
    • SAj Blog
    • SAj Annual Awards
    • SAj Editorial Scholar Program
  • Advocacy
    • AMERSA Advocacy
    • Position Statements
    • Submit a Position Statement
    • Letters of Support
    • Public Comments
  • Sustainability
    • Initiatives
    • Resources
  • Education
    • AMERSA Podcast Series
    • AMERSA Webinars
    • Core Competencies – AMERSA in the 21st Century
    • Resources
  • Awards
    • AMERSA Awards
    • Current Award Winners
    • Past Award Winners

The Authors’ Own Words: Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?

Nov 16, 2019 by AMERSA

The Authors’ Own Words:  

We ask authors to describe their impressions regarding the implications of their accepted work, how their findings will change practice, and what is noteworthy about the work. 

Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?

Kirsten Elin Smith, MSW & Michele Staton, PhD

Substance Abuse Vol. 40, Iss. 2, 2019

“A majority of individuals (68%) enrolled in peer-led residential recovery programs who reported synthetic cannabinoid receptor agonist (SCRA) use were more likely to be younger, White, and to have been arrested and experienced homelessness in the past year compared to those who had not used SCRA. Though this group reported versatile substance use patterns, including use of other novel psychoactive drugs, they did not prefer SCRA to other drugs. Rather, heroin, non-prescribed opioids, and amphetamines were preferred. One reason may be that several adverse side effects were attributed to SCRA use. This latter finding is particularly concerning in that individuals using SCRA to circumnavigate drug monitoring, such as some in this clinical sample reported, may be motivated not to disclose use or seek medical treatment for SCRA-related effects. Indeed, few individuals who reported adverse SCRA side effects also reported seeking medical care. Given that SCRA are typically undetectable via standard drug screens, clinicians should consider alternative assessment methods and remain mindful of how psychiatric symptoms may be influenced by SCRA use. These findings indicate that only a minority of individuals who reported lifetime SCRA use prefer SCRA and intend to use it in the future, perhaps indicating that use of some SCRA compounds will not endure long-term.“

Follow us on twitter to stay up to date with SAj, upcoming publications, and more!

Filed Under: SAj Blog, The Authors' Own Words, Uncategorized Tagged With: cannabinoid, recovery, synthetic drugs

Copyright © 2025
Site by: web360